Pharmacological investigation of 'HIM-CHX': A herbal combination in the experimental muscle wasting condition.
Animals
Antioxidants
/ analysis
Boswellia
/ chemistry
Cissus
/ chemistry
Drug Evaluation, Preclinical
Gait Analysis
Locomotion
/ drug effects
Male
Muscle Strength
/ drug effects
Muscle, Skeletal
/ drug effects
Phytotherapy
Plant Extracts
/ administration & dosage
Rats, Wistar
Sarcopenia
/ drug therapy
Toxicity Tests, Acute
Withania
/ chemistry
Gait
Grip strength
Myostatin
Proinflammatory cytokine
Sarcopenia
Journal
Experimental gerontology
ISSN: 1873-6815
Titre abrégé: Exp Gerontol
Pays: England
ID NLM: 0047061
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
received:
22
03
2019
revised:
04
07
2019
accepted:
14
07
2019
pubmed:
19
7
2019
medline:
17
7
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
Muscle wasting diseases are gradually increasing with the increase in global life expectancy. This study was designed to evaluate the efficacy of HIM-CHX, a herbal combination of Boswellia serrata, Cissus quadrangularis, and Withania somnifera, on Sarcopenia. The effects of HIM-CHX on parameters such as muscle mass, grip strength, motor coordination, gait, locomotor activity and endurance were measured in rats. In addition to this, inflammatory cytokines, myokine and growth hormone levels were also evaluated. In the first experiment, HIM-CHX was administered orally to rats at the dose of 125, 250, and 500 mg/kg body weight for 12 weeks. At the end of the treatment period, muscle mass, grip strength, motor coordination and proinflammatory cytokines were evaluated. In the second experiment, HIM-CHX was administered orally at a dose of 500 mg/kg body weight for 4 weeks and gait analysis, locomotor activity, endurance and endogenous antioxidant activity were evaluated. The animals treated with HIM-CHX showed a significant improvement in gastrocnemius muscle weight, carcass weight, gait, locomotor activity and endurance. HIM-CHX exerts its effect by reducing the levels of TNF-α, IL-6, and Myostatin while increasing the IGF-1 levels which are the typical biomarkers of muscle wasting. Furthermore, the study findings indicate that HIM-CHX has the potential to correct the pathophysiological changes associated with sarcopenia.
Identifiants
pubmed: 31319130
pii: S0531-5565(19)30217-7
doi: 10.1016/j.exger.2019.110663
pii:
doi:
Substances chimiques
Antioxidants
0
Plant Extracts
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110663Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.